Cargando…
Glycogen phosphorylase inhibitor, 2,3‐bis[(2E)‐3‐(4‐hydroxyphenyl)prop‐2‐enamido] butanedioic acid (BF142), improves baseline insulin secretion of MIN6 insulinoma cells
Type 2 diabetes mellitus (T2DM), one of the most common metabolic diseases, is characterized by insulin resistance and inadequate insulin secretion of β cells. Glycogen phosphorylase (GP) is the key enzyme in glycogen breakdown, and contributes to hepatic glucose production during fasting or during...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508380/ https://www.ncbi.nlm.nih.gov/pubmed/32960890 http://dx.doi.org/10.1371/journal.pone.0236081 |
_version_ | 1783585408792133632 |
---|---|
author | Nagy, Lilla Béke, Ferenc Juhász, László Kovács, Tünde Juhász-Tóth, Éva Docsa, Tibor Tóth, Attila Gergely, Pál Somsák, László Bai, Péter |
author_facet | Nagy, Lilla Béke, Ferenc Juhász, László Kovács, Tünde Juhász-Tóth, Éva Docsa, Tibor Tóth, Attila Gergely, Pál Somsák, László Bai, Péter |
author_sort | Nagy, Lilla |
collection | PubMed |
description | Type 2 diabetes mellitus (T2DM), one of the most common metabolic diseases, is characterized by insulin resistance and inadequate insulin secretion of β cells. Glycogen phosphorylase (GP) is the key enzyme in glycogen breakdown, and contributes to hepatic glucose production during fasting or during insulin resistance. Pharmacological GP inhibitors are potential glucose lowering agents, which may be used in T2DM therapy. A natural product isolated from the cultured broth of the fungal strain No. 138354, called 2,3-bis(4-hydroxycinnamoyloxy)glutaric acid (FR258900), was discovered a decade ago. In vivo studies showed that FR258900 significantly reduced blood glucose levels in diabetic mice. We previously showed that GP inhibitors can potently enhance the function of β cells. The purpose of this study was to assess whether an analogue of FR258900 can influence β cell function. BF142 (Meso-Dimethyl 2,3‐bis[(E)‐3‐(4‐acetoxyphenyl)prop‐2‐enamido]butanedioate) treatment activated the glucose-stimulated insulin secretion pathway, as indicated by enhanced glycolysis, increased mitochondrial oxidation, significantly increased ATP production, and elevated calcium influx in MIN6 cells. Furthermore, BF142 induced mTORC1-specific phosphorylation of S6K, increased levels of PDX1 and insulin protein, and increased insulin secretion. Our data suggest that BF142 can influence β cell function and can support the insulin producing ability of β cells. |
format | Online Article Text |
id | pubmed-7508380 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-75083802020-10-01 Glycogen phosphorylase inhibitor, 2,3‐bis[(2E)‐3‐(4‐hydroxyphenyl)prop‐2‐enamido] butanedioic acid (BF142), improves baseline insulin secretion of MIN6 insulinoma cells Nagy, Lilla Béke, Ferenc Juhász, László Kovács, Tünde Juhász-Tóth, Éva Docsa, Tibor Tóth, Attila Gergely, Pál Somsák, László Bai, Péter PLoS One Research Article Type 2 diabetes mellitus (T2DM), one of the most common metabolic diseases, is characterized by insulin resistance and inadequate insulin secretion of β cells. Glycogen phosphorylase (GP) is the key enzyme in glycogen breakdown, and contributes to hepatic glucose production during fasting or during insulin resistance. Pharmacological GP inhibitors are potential glucose lowering agents, which may be used in T2DM therapy. A natural product isolated from the cultured broth of the fungal strain No. 138354, called 2,3-bis(4-hydroxycinnamoyloxy)glutaric acid (FR258900), was discovered a decade ago. In vivo studies showed that FR258900 significantly reduced blood glucose levels in diabetic mice. We previously showed that GP inhibitors can potently enhance the function of β cells. The purpose of this study was to assess whether an analogue of FR258900 can influence β cell function. BF142 (Meso-Dimethyl 2,3‐bis[(E)‐3‐(4‐acetoxyphenyl)prop‐2‐enamido]butanedioate) treatment activated the glucose-stimulated insulin secretion pathway, as indicated by enhanced glycolysis, increased mitochondrial oxidation, significantly increased ATP production, and elevated calcium influx in MIN6 cells. Furthermore, BF142 induced mTORC1-specific phosphorylation of S6K, increased levels of PDX1 and insulin protein, and increased insulin secretion. Our data suggest that BF142 can influence β cell function and can support the insulin producing ability of β cells. Public Library of Science 2020-09-22 /pmc/articles/PMC7508380/ /pubmed/32960890 http://dx.doi.org/10.1371/journal.pone.0236081 Text en © 2020 Nagy et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Nagy, Lilla Béke, Ferenc Juhász, László Kovács, Tünde Juhász-Tóth, Éva Docsa, Tibor Tóth, Attila Gergely, Pál Somsák, László Bai, Péter Glycogen phosphorylase inhibitor, 2,3‐bis[(2E)‐3‐(4‐hydroxyphenyl)prop‐2‐enamido] butanedioic acid (BF142), improves baseline insulin secretion of MIN6 insulinoma cells |
title | Glycogen phosphorylase inhibitor, 2,3‐bis[(2E)‐3‐(4‐hydroxyphenyl)prop‐2‐enamido] butanedioic acid (BF142), improves baseline insulin secretion of MIN6 insulinoma cells |
title_full | Glycogen phosphorylase inhibitor, 2,3‐bis[(2E)‐3‐(4‐hydroxyphenyl)prop‐2‐enamido] butanedioic acid (BF142), improves baseline insulin secretion of MIN6 insulinoma cells |
title_fullStr | Glycogen phosphorylase inhibitor, 2,3‐bis[(2E)‐3‐(4‐hydroxyphenyl)prop‐2‐enamido] butanedioic acid (BF142), improves baseline insulin secretion of MIN6 insulinoma cells |
title_full_unstemmed | Glycogen phosphorylase inhibitor, 2,3‐bis[(2E)‐3‐(4‐hydroxyphenyl)prop‐2‐enamido] butanedioic acid (BF142), improves baseline insulin secretion of MIN6 insulinoma cells |
title_short | Glycogen phosphorylase inhibitor, 2,3‐bis[(2E)‐3‐(4‐hydroxyphenyl)prop‐2‐enamido] butanedioic acid (BF142), improves baseline insulin secretion of MIN6 insulinoma cells |
title_sort | glycogen phosphorylase inhibitor, 2,3‐bis[(2e)‐3‐(4‐hydroxyphenyl)prop‐2‐enamido] butanedioic acid (bf142), improves baseline insulin secretion of min6 insulinoma cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508380/ https://www.ncbi.nlm.nih.gov/pubmed/32960890 http://dx.doi.org/10.1371/journal.pone.0236081 |
work_keys_str_mv | AT nagylilla glycogenphosphorylaseinhibitor23bis2e34hydroxyphenylprop2enamidobutanedioicacidbf142improvesbaselineinsulinsecretionofmin6insulinomacells AT bekeferenc glycogenphosphorylaseinhibitor23bis2e34hydroxyphenylprop2enamidobutanedioicacidbf142improvesbaselineinsulinsecretionofmin6insulinomacells AT juhaszlaszlo glycogenphosphorylaseinhibitor23bis2e34hydroxyphenylprop2enamidobutanedioicacidbf142improvesbaselineinsulinsecretionofmin6insulinomacells AT kovacstunde glycogenphosphorylaseinhibitor23bis2e34hydroxyphenylprop2enamidobutanedioicacidbf142improvesbaselineinsulinsecretionofmin6insulinomacells AT juhasztotheva glycogenphosphorylaseinhibitor23bis2e34hydroxyphenylprop2enamidobutanedioicacidbf142improvesbaselineinsulinsecretionofmin6insulinomacells AT docsatibor glycogenphosphorylaseinhibitor23bis2e34hydroxyphenylprop2enamidobutanedioicacidbf142improvesbaselineinsulinsecretionofmin6insulinomacells AT tothattila glycogenphosphorylaseinhibitor23bis2e34hydroxyphenylprop2enamidobutanedioicacidbf142improvesbaselineinsulinsecretionofmin6insulinomacells AT gergelypal glycogenphosphorylaseinhibitor23bis2e34hydroxyphenylprop2enamidobutanedioicacidbf142improvesbaselineinsulinsecretionofmin6insulinomacells AT somsaklaszlo glycogenphosphorylaseinhibitor23bis2e34hydroxyphenylprop2enamidobutanedioicacidbf142improvesbaselineinsulinsecretionofmin6insulinomacells AT baipeter glycogenphosphorylaseinhibitor23bis2e34hydroxyphenylprop2enamidobutanedioicacidbf142improvesbaselineinsulinsecretionofmin6insulinomacells |